Company Third Harmonic Bio, Inc.

Equities

THRD

US88427A1079

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-10 EDT			5-day change	1st Jan Change
11.9 ^USD	-3.25%		+1.71%	+8.48%

03-28	Third Harmonic Bio, Inc. Appoints Geoff Mcdonough to Its Board of Directors	CI
03-26	Third Harmonic Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Third Harmonic Bio, Inc. is a biopharmaceutical company. The Company is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of inflammatory disorders including urticaria, asthma and gastrointestinal disorders, among others. The Company is advancing its lead product candidate, THB335, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway and gastrointestinal tract. THB335 is a potent, highly selective, oral small molecule KIT inhibitor with a promising preclinical product profile.

Number of employees: 30

Managers	Title	Age	Since
Natalie Holles CEO	Chief Executive Officer	51	20-07-31
Julie Person ADM	Chief Administrative Officer	49	22-05-31
Edward Conner CTO	Chief Tech/Sci/R&D Officer	51	22-05-31

Members of the board	Title	Age	Since
Robert Perez BRD	Director/Board Member	59	21-11-30
David Bonita BRD	Director/Board Member	48	20-06-30
Thomas Soloway BRD	Director/Board Member	55	22-06-30
Natalie Holles CEO	Chief Executive Officer	51	20-07-31
Mark Iwicki CHM	Chairman	57	20-04-30
H. Seidel BRD	Director/Board Member	59	19-06-30
Michael Gladstone BRD	Director/Board Member	37	19-03-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	40,714,399	33,679,656 ( 82.72 %)	0	82.72 %

Name	Equities	%	Valuation
Atlas Venture Life Science Advisors LLC 26.79 %	10,907,859	26.79 %	103 M $
BVF, Inc. 10.72 %	4,365,933	10.72 %	41 M $
EcoR1 Capital, LLC 7.817 %	3,182,444	7.817 %	30 M $
NOVARTIS AG 6.491 %	2,642,762	6.491 %	25 M $
RA Capital Management LP 4.993 %	2,033,056	4.993 %	19 M $
Braidwell LP 3.232 %	1,316,018	3.232 %	12 M $
BlackRock Advisors LLC 3.160 %	1,286,405	3.160 %	12 M $
Natalie Holles 2.994 %	1,218,836	2.994 %	12 M $
Vanguard Fiduciary Trust Co. 2.091 %	851,392	2.091 %	8 M $
Boxer Capital LLC 1.842 %	750,000	1.842 %	7 M $

Third Harmonic Bio, Inc.

1700 Montgomery Street Suite 210

94111, San Francisco

http://thirdharmonicbio.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

11.9 USD

Average target price

9.55 USD

Spread / Average Target

-19.75%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
THIRD HARMONIC BIO, INC.	+8.48%	485M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs